scholarly journals INTERIM DATA FROM THE FIRST CLINICAL STUDY OF ADCT-301, A NOVEL PYRROLOBENZODIAZAPINE-BASED ANTIBODY DRUG CONJUGATE, IN RELAPSED/REFRACTORY HODGKIN/NON-HODGKIN LYMPHOMA

2017 ◽  
Vol 35 ◽  
pp. 270-271 ◽  
Author(s):  
S.M. Horwitz ◽  
M.A. Fanale ◽  
A.I. Spira ◽  
K. Havenith ◽  
S. He ◽  
...  
Keyword(s):  
Clinical Study ◽  
Hodgkin Lymphoma ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Non Hodgkin Lymphoma ◽  
Antibody Drug

scholarly journals DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

2013 ◽  
Vol 12 (7) ◽  
pp. 1255-1265 ◽  
Author(s):  
Dongwei Li ◽  
Kirsten Achilles Poon ◽  
Shang-Fan Yu ◽  
Randall Dere ◽  
MaryAnn Go ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Potential Treatment ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Non Hodgkin Lymphoma ◽  
Antibody Drug

Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

2022 ◽  
pp. clincanres.3261.2021
Author(s):  
Alex F. Herrera ◽  
Manish R. Patel ◽  
John M. Burke ◽  
Ranjana Advani ◽  
Bruce D. Cheson ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Dose Escalation ◽  
Phase 1 ◽  
Antibody Drug Conjugate ◽  
Dose Escalation Study ◽  
Drug Conjugate ◽  
Non Hodgkin Lymphoma ◽  
Antibody Drug

scholarly journals The HB22.7–vcMMAE antibody–drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity

2016 ◽  
Vol 65 (10) ◽  
pp. 1169-1175 ◽  
Author(s):  
Mastewal Abuhay ◽  
Jason Kato ◽  
Emily Tuscano ◽  
Gustavo A. Barisone ◽  
Ranjit S. Sidhu ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Systemic Toxicity ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Non Hodgkin Lymphoma ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document